川芎嗪联合化疗治疗中晚期肝癌的疗效及对患者BDNF水平的影响研究  

Curative efficacy of tetramethylpyrazine in combination with chemotherapy in treatment of medium and advanced liver cancer and its effects on level of BDNF

作　　者：徐世英[1] 曾敬怀[1] 蒋英蓝[1] 秦春宏[2] 

机构地区：[1]泸州市人民医院药剂科,四川泸州646000 [2]南华大学附属第二医院普外科,湖南衡阳421001

出　　处：《中国生化药物杂志》2015年第9期133-135,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家自然科学基金资助项目(81172365)

摘　　要：目的探讨川芎嗪联合化疗治疗中晚期肝癌的疗效及对患者脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)水平的影响。方法选取2011年1月至2012年6月接受治疗的90例中晚期肝癌患者作为研究对象,按照治疗方案分为对照组42例和观察组48例。对照组给予化疗栓塞(transcatheter hepatic arterial chemoembolization,TACE)治疗,观察组在对照组基础上联合应用川芎嗪治疗。观察比较2组患者肿瘤近期疗效、长期疗效、BDNF水平及不良反应发生情况。结果治疗后,观察组近期治疗总有效率高于对照组(83.3%vs 64.3%,P<0.05)。随访3年,对照组1年、2年和3年生存率分别为66.7%、59.5%和30.9%,观察组的分别为75.0%、66.7%和52.1%。2组患者1年、2年生存率比较差异无统计学意义,而观察组3年生存率显著高于对照组(P<0.05)。治疗后,观察组BDNF水平显著低于对照组(P<0.05)。治疗期间,2组患者肝功能恶化、腹痛腹泻、恶心呕吐、发热头痛等不良反应发生率组间比较差异无统计学意义。结论川芎嗪联合化疗栓塞治疗中晚期肝癌疗效可靠,能够一定程度提高肿瘤近期有效率及生存率,明显降低患者BDNF水平,且不增加不良反应发生率,临床上值得进一步研究。Objective To investigate curative efficacy of tetramethylpyrazine in combination with chemotherapy in treatment of medium and advanced liver cancer and its effects on level of brain-derived neurotrophic factor（ BDNF）. Methods 90 patients of medium and advanced liver cancer who received therapy from January 2011 to June 2012 were selected as research objects. According to therapeutic schemes,those patients were divided into the control group（ n = 42） and the observation group（ n = 48）. The control group was treated with transcatheter hepatic arterial chemoembolization（ TACE）,while the observation group was treated with tetramethylpyrazine in combination with TACE. Then,the short-term curative efficacy,long-term curative efficacy,level of BDNF and adverse reactions were compared. Results The total short-term therapeutic efficacy ratio in the observation group was statistically higher than that in the control group（ 83. 3% vs 64. 3%,P〈0. 05）. During the three-year follow-up,the one-year and two-year survival rate in the observation group was statistically same with that in the control group respectively（ 75. 0% vs 66. 7%,66. 7% vs 59. 5%）,while the three-year survival rate was statistically higher than that in the control group（ 52. 1% vs 30. 9%,P〈0. 05）. After treatment,in comparison with the control group,level of BDNF in the observation group was statistically lower（ P〈0. 05）. During treatment,incidences of liver function deterioration,abdo minal pain and diarrhea,nausea and vomiting,fever and headache in two groups were statistically same. Conclusion Tetramethylpyrazine in combination with TACE is effective for medium and advanced liver cancer,which can increase short-term and survival rate to some extent,significantly reduce level of BDNF with not increasing incidence of adverse reactions.

关 键 词：川芎嗪 化疗栓塞 中晚期肝癌 脑源性神经营养因子 

分 类 号：R735.7[医药卫生—肿瘤]